JPRN-jRCT2080221054未知2 期
A Phase II study of TSU-68 in patient with hepatocellular carcinoma who are treated by transcatheter arterial chemoembolization (TACE)
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)20 years or older.
- •2)Histopathologically confirmed HCC or diagnosed as HCC by the CT imaging.
- •3)Not indicated to treatment with curative surgery or percutaneous ablation(such as RFA, PEIT or PMCT).
- •4)Adequate oral intake.
- •5)Life expectancy of at least 3 months.
- •6)P.S.:0-2
排除标准
- •1)Patient has ascites, pleural effusions or pericardial fluid requiring drainage .
- •2)Patient has clinical symptoms of hepatic encephalopathy.
- •3)Patient has active or uncontrolled clinically serious infection excluding
- •chronic hepatitis .
- •4)Patient has active double cancer.
- •5)Have participated in other clinical trials within 4 weeks prior to registration.
研究者
相似试验
进行中（未招募）
1 期
A Study of LY2157299 in Patients With Liver CancerCarcinoma, hepatocellularMedDRA version: 20.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864EUCTR2010-022338-10-DEEli Lilly and Company204
未知
2 期
An early phase II study of TSU-68 in combination with docetaxel in patients with advanced and metastatic breast cancer progressing anthracycline containing regimen.Breast cancerJPRN-jRCT2080221143Taiho Pharmaceutical Co., Ltd.19
未知
3 期
Clinical study of SM-11355 in patients with hepatocellular carcinoma (Phase III Study)Hepatocellular carcinomaJPRN-jRCT2080220609Dainippon Sumitomo Pharma Co., Ltd.
招募中
不适用
Prospective clinical study of EUS-guided hepaticogastrostomy for malignant biliary obstruction as primary drainagenresectable malignant biliary obstructionJPRN-UMIN000044993Osaka Medical and Pharmaceutical University18
未知
2 期
A randomized phase II trial of TSU-68 in patients with advanced gastric cancerGastric cancerJPRN-jRCT2080221290Taiho Pharmaceutical Co., Ltd.92